Extension data confirm the observed safety and tolerability profile from Phase 2 studies and further support the potential for deucrictibant to become a preferred therapy for the management of HAE Long-term prophylaxis extension data of deucrictibant shows attack reduction is maintained for over one year; open-label extension participants experienced a 93% reduction in attacks compared to baseline Long-term on-demand extension data of deucrictibant immediate-release capsule shows median onset of symptom rel ...

Haemonetics (HAE) has been on a downward spiral lately with significant selling pressure. After declining 15.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock ...

Haemonetics Corporation (HAE) recently announced the full market release of its VASCADE MVP XL — a mid-bore venous closure system. The VASCADE MVP XL system will now be available to U.S. hospitals as the newest addition to the company's VASCADE portfolio of vascular closure systems. With the full market release underway and an ongoing clinical trial program, the company is well-positioned to broaden the indications for the VASCADE MVP XL system to even larger access points. The latest development is expecte ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here's the latest list of major oversold player ...

BOSTON, Aug. 15, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, today announced the full market release of its VASCADE MVP® XL mid-bore venous closure system. The VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable c ...

Haemonetics Corporation (HAE) delivered adjusted earnings per share (EPS) of $1.02 in the first quarter of fiscal 2025, down 2.9% year over year. The bottom line missed the Zacks Consensus Estimate by 0.9%. On a GAAP basis, the EPS was 74 cents compared with 80 cents in the prior-year quarter. Total Revenues Revenues increased 8% (up 2.8% on an organic basis) to $336.2 million in the first quarter of fiscal 2025. The top line beat the Zacks Consensus Estimate by 0.1%. Segments in Detail At Plasma, revenues ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a ...

Haemonetics (HAE) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

财务数据和关键指标变化 - 第一季度收入为3.36亿美元,同比增长8%,其中有机增长3% [9] - 调整后每股收益为1.02美元,同比下降3% [33] - 调整后毛利率为55.3%,同比增加110个基点,主要受益于医院业务占比上升 [28] - 调整后营业费用为1.149亿美元,同比增加17%,主要由于最近收购OpSens和Attune Medical以及增加投资 [29] - 调整后营业利润为7100万美元,同比增加0.8%,调整后营业利润率为21.1%,同比下降150个基点,主要受汇率影响和营业费用增加 [30] - 调整后净利润为5240万美元,同比下降2% [33] - 预计2025财年调整后每股收益为4.45-4.75美元,中值受利息费用、汇率和税率等因素影响约为0.34美元 [34] 各条业务线数据和关键指标变化 血浆业务 - 第一季度收入下降3%,主要受CSL计划过渡的影响 [13] - 北美处置收入下降5%,但剔除过渡和临时客户中心停运的影响,美国采集量增长高个位数 [13] - 北美软件和欧洲耗材收入均实现两位数增长 [13] - 预计2025财年血浆业务收入将下降3%-6% [16] 血液中心业务 - 第一季度收入下降2%,其中血浆业务收入增长3%,全血业务收入下降14% [16][17] - 预计2025财年血液中心业务收入将下降5%-7% [17] 医院业务 - 第一季度收入增长31%,其中有机增长13% [18] - 血管闭合设备收入增长68%,有机增长19% [18][19] - 新收购产品贡献收入1800万美元 [22][31] - 预计2025财年医院业务收入增长27%-32%,有机增长13%-16% [25] 各个市场数据和关键指标变化 - 日本市场VASCADE产品表现出色,已进入100多家医院 [84] - 欧洲市场VASCADE产品渗透较慢,主要受制于不同国家的报销政策和治疗方法差异 [85][86] 公司战略和发展方向及行业竞争 - 公司持续推进创新,推出新产品,拓展进入高增长市场,提升财务表现 [40] - 公司完成债务融资,增强资本实力和灵活性,为未来有机或非有机增长机会做好准备 [41] - 公司致力于实现长期战略目标,打造可持续增长引擎,为股东创造价值 [42] - 血浆行业长期需求旺盛,未来10年分馏产能将增加6%以上 [44][45] - 脉冲场消融技术是市场颠覆性力量,但对公司介入技术组合是净正面影响 [48][49] 管理层对经营环境和未来前景的评论 - 公司在动荡市场环境中保持韧性,展现业务多元化优势 [90][91][92] - 血浆、TEG和介入技术三大业务板块预计将在未来恢复增长势头 [90][91][92] 其他重要信息 - 公司完成OpSens和Attune Medical两家公司的收购整合,预计将带来协同效应 [31] - 公司完成债务再融资,包括发行7亿美元可转债和重新安排信用额度,增强财务灵活性 [36][37][38] 问答环节重要的提问和回答 问题1 **Anthony Petrone 提问** - 血浆供需平衡情况如何,客户是否仍在补充库存 [43][44][45] - CSL计划过渡的进度是否符合预期 [46] **Chris Simon 回答** - 长期来看,血浆分馏产能将持续增加,需求旺盛 [44][45] - 短期内客户库存补充和降低采集成本是主要关注点,有利于公司产品升级和市场份额提升 [45] - CSL计划过渡进度符合预期,公司与之有明确协议 [46] 问题2 **Mike Matson 提问** - 无需Persona升级的客户是否仍有价格优势 [52][53] - VASCADE MVP XL的定价策略和销售团队整合情况 [54][55][56][57] **Chris Simon 回答** - 无需Persona升级的客户仍有价格优势,但公司正加快Persona的推广 [52][53] - VASCADE MVP XL有适度的价格溢价,销售团队整合工作进展良好,公司采取谨慎态度确保顺利过渡 [54][55][56][57] 问题3 **Joanne Wuensch 提问** - 目前手动压迫仍是主要的血管闭合方式,公司如何推动VASCADE的使用 [76][77][78][80] - 为何认为VASCADE XL更适用于脉冲场消融 [81] **Chris Simon 回答** - 公司已渗透到主要医院的80%,但VASCADE的使用率仍在40%左右,公司正积极推动转换 [77][78][80] - 公司在脉冲场消融应用中进行了充分的动物试验,VASCADE XL产品性能优异 [81]

Haemonetics (HAE) came out with quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $1.05 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -0.97%. A quarter ago, it was expected that this provider blood management systems for health care providers and blood collectors would post earnings of $0.88 per share when it actually produced earnings of $0.90, deli ...